Molecular Partners Ag (MOLN) has released an update.
Molecular Partners AG, a biotech firm focusing on novel DARPin therapeutics, has announced its Annual General Meeting for April 17, 2024, in Zurich-Schlieren, Switzerland. The company highlighted its commitment to addressing complex medical challenges and detailed a financial calendar with key dates for 2024. Additionally, they provided insight into ongoing and future clinical developments in oncology, along with the potential benefits of their proprietary programs.
For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.
